30 closest matches · ranked by relevance
Thalassemia, Non-transfusional-dependent Thalassemia (NTDT), Myeloplastic Dysplasia (MDS), Other Anemia
Primary: Percentage of Participants With Cardiac and Liver Iron Overload. — 10; 22; 4; 0 Percentage of participants
Iron Overload · Excessive Body Iron Burden
Primary: Hepatic Iron Content in the Liver Using Liver Biopsy — 19.8 mcg
Acute Undifferentiated Leukemia · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission
Primary: Changes in Mean Neutrophil Values (as Measured by Lab) for Arm 1 (Other Arms Were Used for Calibration Only) — 7.8 10^9 Neutrophils per Liter
Iron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major
Primary: Number of Participants With Adverse Events, Serious Adverse Events and Deaths as a Measure of Safety and Tolerability — 25; 3; 0 Participants
Chronic Anemia · Transfusional Hemosiderosis
Primary: Absolute Change From Baseline in Liver Iron Concentration (LIC) to Year 1 — -10.9 mg Fe/g dw
Cardiac Iron Overload
Primary: Change in Cardiac Iron Content From Baseline to Month 12 — 1.09 ratio
Heart Transplant Recipients
Primary: Peak Oxygen Consumption — 23.9; 22.0 ml/kg/min
Thalassemia Major With Severe Transfusional Iron Overload
Primary: Number of Participants With Improvement in Liver Iron Concentration — 3 Participants
Transfusional Iron Overload · Transfusional Hemosiderosis
Primary: Core Study: Change From Baseline in Myocardial T2* (Magnetic Resonance T2-star (T2*) Technique for the Measurement of Tissue Iron) After 12 Months Treatment — 1.12; 1.07…
Myelodysplastic Syndrome · Iron Overload
Primary: Number of Participants Reporting Adverse Events — 171 Participants
Iron Deficiency
Primary: 51-Chromium 24-hour Post-transfusion RBC Recovery of Units — 1.6; -0.4 percentage change
Thalassemia · Sickle Cell Disease · Diamond Blackfan Anemia
Primary: Safety Profile of Deferasirox Based Upon Drug Administration and Reporting of Serious Adverse Events — 0; 0; 1; 4 Participants
Sickle Cell Disease · Iron Overload · Hemolytic Anemia
Primary: The Number of Participants With Adverse Events (AEs) in the First 24 Weeks of Treatment — 30; 17; 30; 8 participants
Iron Overload · Hereditary Hemochromatosis
Primary: Absolute Change of Serum Ferritin From Baseline to the End of Extension, by Dose Cohort (Extension Per-protocol Population) — -389.1; -610.5; -571.6 µg/L
Beta Thalassemia Major Anemia · Iron Overload
Primary: The Percentage of Patients in Each Treatment Group Who Still Have a Serum Ferritin Level < 1000 Micrograms Per Liter (μg/L) at Month 12 — 21; 12 Participants — p=0.0446
Iron Overload
Primary: Number of Participants With Selected Gastrointestinal Disorders up to 24 Weeks — 0; 0; 0; 0 Participants
Superficial Siderosis
Primary: Number of Participants Who Show Stability, Improvement or Decline in Self Reported Hearing — 13; 18; 0 Participants
Iron Overload Due to Repeated Red Blood Cell Transfusions
Primary: The Percentage of Patients in Each Treatment Group Who Experience Post-dose Increases in Liver Enzyme Levels That Are Considered a Safety Concern. — 0; 0; 0; 0…
Liver Iron Overload
Primary: The Relative Change From Baseline in Liver Iron Content (LIC) After Prolonged Use of Deferasirox — -21.9; -23.1 Percent change
Iron Overload
Primary: Occurrence of Adverse Events — 212 Adverse Events
Impaired Renal Function
Primary: Area Under the Plasma Concentration-time Curve (AUC) of SSP-004184 — 445892.7; 932688.3; 1531185.8; 1261081.6 ng*hr/ml
Congenital Heart Disease
Primary: Mean Arterial Lactate Level — 1.4; 1.4 mmol/L
Pediatric Congenital Heart Disease
Primary: Composite Image Quality Score Among 7 Anatomical Structures. — 3.9; 2.7 score on a scale
Trauma · ICU Anemia
Primary: RBC Transfusion — 47; 55 participants
Iron Deficiency Anemia
Primary: Number of Weeks Until Transferrin Saturation (TSAT) and Ferritin Stabilize — 2 weeks
Beta-thalassemia · Iron Overload
Primary: Magnetic Resonance Imaging (MRI) T2* and Absolute Change From Baseline in MRI T2* — 9.92; 11.73; 1.77; 11.93 milliseconds (msec)
Transfusional Iron Overload · Beta-thalassemia
Primary: Change From Baseline in Liver Iron Concentration (LIC) at 96 Weeks — -1.75 mg/g — p=0.0765
Sickle Cell Disease
Primary: Proportion of Biochemically Old Red Cell Units — 0.71; 0.86 proportion biologically old units — p=0.051
Myelodysplastic Syndromes · Iron Overload
Primary: Number of Participants With Adverse Events and Serious Adverse Events — 24; 11 Participants
Chronic Iron Overload
Primary: Percentage of Successfully Chelated Patients — 69; 80 Participants